Adaptive Biotechnologies upgraded by Goldman with a new price target
$ADPT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Goldman upgraded Adaptive Biotechnologies from Neutral to Buy and set a new price target of $9.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2025 | $21.00 | Equal-Weight | Morgan Stanley |
| 9/30/2025 | $20.00 | Buy | Guggenheim |
| 6/18/2025 | $15.00 | Buy | Craig Hallum |
| 3/21/2025 | $9.00 | Neutral → Buy | Goldman |
| 7/5/2023 | $15.00 | Overweight | JP Morgan |
| 1/5/2023 | $15.00 | Sector Outperform | Scotiabank |
| 12/21/2022 | $7.50 → $14.00 | Neutral → Overweight | Piper Sandler |
| 8/25/2022 | $8.00 | Underperform | Credit Suisse |
For Immediate Release: March 05, 2021 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by Adaptive Biotechnologies. The T-Detect COVID Test is a next generation sequencing based (NGS) test to aid in identifying individuals with an adaptive T cell immune response to SARS-CoV-2, indicating recent or prior infection with SARS-CoV-2. “Today’s authorization further und
Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibilityAdditional proceeds used to pay for the capped call with a premium of 100% and to repurchase $25 million of common stock to reduce potential dilutionRemaining capital to be used for general corporate purposes and opportunistic initiatives in the MRD business SEATTLE, June 17, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT) today announced the pricing of its offering of $300 million aggregate principal amount of 0% convertible senior notes due 2031 (the "notes") in a private offering to persons reasonably believed to be qualified
SEATTLE, June 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced its intention to pursue a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses. The company is evaluating strategic and structural alternatives for Immune Medicine to support its growth strategy, capital needs, and value creation opportunities outside of Adaptive, and expects to identify its preferred path to separation by year-end 2026. Since establishing MRD and Immune Medicine as separate ope
Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibilityAdditional proceeds used to pay for the capped call with a premium of at least 75% and to repurchase up to $25 million of common stock to reduce potential dilutionRemaining capital to be used for general corporate purposes and opportunistic initiatives in the MRD business SEATTLE, June 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT) today announced its intention to offer, subject to market and other conditions, $250 million aggregate principal amount of convertible senior notes due 2031 (the "notes") in a private offering to
8-K - Adaptive Biotechnologies Corp (0001478320) (Filer)
8-K - Adaptive Biotechnologies Corp (0001478320) (Filer)
8-K - Adaptive Biotechnologies Corp (0001478320) (Filer)
4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
Morgan Stanley resumed coverage of Adaptive Biotechnologies with a rating of Equal-Weight and set a new price target of $21.00
Guggenheim initiated coverage of Adaptive Biotechnologies with a rating of Buy and set a new price target of $20.00
Craig Hallum initiated coverage of Adaptive Biotechnologies with a rating of Buy and set a new price target of $15.00
Cohen to serve as Chair of the Audit Committee Grindr Inc. (NYSE:GRND), the Global Gayborhood in Your Pocket™, today announced the appointment of Chad Cohen, former Chief Financial Officer of Zillow Group Inc. (NASDAQ:Z) and Adaptive Biotechnologies Corp. (NASDAQ:ADPT) and Founding Partner of Scala Advisors, LLC, to Grindr's Board of Directors as of June 3, 2025. Cohen was also appointed to serve as the Chair of Grindr's Audit Committee. A seasoned public company finance executive and board member, Cohen has helped grow several multi-billion dollar technology companies, including multiple leading consumer Internet brands. Prior to his current role, Cohen served as the Chief Financial Of
SEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointment of Tycho Peterson as chief financial officer (CFO). Mr. Peterson brings several decades of financial leadership and experience within the life science and diagnostic industries. "Tycho has been a leader in this space over the last two decades, during which disruptive technologies such as genomic sequencing and artificial intelligence have driven a complete paradigm shift in diagnostics and precision medic
SEATTLE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointment of Nitin Sood to the newly created position of chief commercial officer, effective immediately. Nitin brings more than 15 years of proven commercial experience at leading life sciences and diagnostics companies, most recently at Guardant Health. "Adaptive has set the stage for commercial success with well-defined growth strategies and a solid pipeline for our current research and diagnostic products. Nit
SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2026. "We delivered strong first quarter results based on accelerating adoption of MRD across both clinical testing and drug development. Our performance reinforces our market leadership position and the differentiated value of our platform," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "With disciplined e
SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2026 after market close on Tuesday, May 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours a
SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 was an outstanding year for Adaptive, marked by strong execution and meaningful progress across the business," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "We delivered 46% revenue growth and achieved profitability in our MRD business, while advancing our Immune Medici
SC 13G - Adaptive Biotechnologies Corp (0001478320) (Subject)
SC 13G/A - Adaptive Biotechnologies Corp (0001478320) (Subject)
SC 13G/A - Adaptive Biotechnologies Corp (0001478320) (Subject)